Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa

Wang, Na; Shi, Dandan; Li, Na; Hu, Qi

doi:10.1080/07853890.2021.1999492

Cited by 12 publications

(11 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result of electrophoresis performed in placenta previa, VEGF level increased. 25,47 It has been reported that VEGF, which increases in response to placental hypoxia, is not functional during the pathogenesis of preeclampsia. Moreover, since the ligand-receptor binding is impaired, the amount of free VEGF in the preeclamptic placenta increases, impairing vascular function as a result of endothelial cell damage.…”

Section: Discussionmentioning

confidence: 99%

“…24 They suggested that VEGF and soluble fms-like tyrosine kinase-1 levels are important for diagnosing placenta previa and can be considered additional parameters to differentiate between placenta accreta and increta. 25 Moreover, the increase in the expression of high mobility group box protein 1 in the placenta may be related to the pathogenesis of placenta previa by regulating the expression of the proangiogenic factor VEGF. 26 In another study, VEGF and leptin levels in 2 nd -trimester amniotic fluid samples taken between 16 and 20 weeks of pregnancy were compared with a control group at 37 weeks.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of NF-κB and VEGF in normal placenta and placenta previa patients

2022

View full text Add to dashboard Cite

Background. Placenta previa is a pregnancy condition associated with the development of complications related to placental insufficiency, including hypertension, preeclampsia and perinatal mortality. Dysfunction in uteroplacental arteries causes the release of cytokines, leukotrienes and immunomodulatory hormones, which leads to an inflammatory reaction.Objectives. The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway and vascular endothelial growth factor (VEGF) are known to play crucial roles in inflammation and angiogenetic regulation. This study aimed to demonstrate the morphometric and immunohistochemical effects on inflammation and angiogenesis underlying placenta previa. Materials and methods.Twenty pregnant patients with placenta previa and 20 healthy pregnant patients, all between 30 and 38 weeks gestational age, were included in the study. The gestational age of the pregnancies was determined according to the last date of menstruation and/or ultrasonographic measurements. Blood samples and clinical data were obtained from the prenatal patient groups. Samples were taken from the connecting stem region from both groups.Results. The mean difference between the control and placenta previa patients was statistically significant for the parameters of blood vessels in villi, diameter of floating small villus, decidual cells, syncytial knots, congestion in blood vessels, fibrinoid accumulation, and inflammation. Significant degeneration and apoptotic changes in the syncytial cells of the root villi and an increase in syncytial nodes and bridges were observed in the placenta previa specimens. In the connecting stem region of the placenta previa samples, blood vessel dilatation, endothelial cell hyperplasia and a higher number of syncytial nodes were observed. In the immuno histochemical examination of the placenta previa samples, an increase in NF-κB and VEGF expression was observed in the endothelial cells, syncytial cells and Hofbauer cells.Conclusions. Vascular endothelial growth factor was found to stimulate endothelial cell proliferation and migration, and to significantly affect angiogenesis during the developmental process of the placenta and remodeling of the uterine vessels, inducing NF-κB signaling and apoptotic development during cytotrophoblastic invasion in the vascularization of the placenta.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Expression of NF-κB and VEGF in normal placenta and placenta previa patients

2022

View full text Add to dashboard Cite

show abstract

“…Since VEGF cannot diffuse across biological membranes after binding to circulating sFlt-1, it cannot conduct signaling. 31 sFlt-1 was significantly increased in the preeclamptic placenta at 11 weeks of gestation, with increased expression beginning 5 weeks before the onset of clinical symptoms. 32 Supernatant analysis of placental villus explant in preeclampsia showed a 4-fold increase in sFlt-1 levels compared with normal pregnancy.…”

Section: Placental Growth Factor (Plgf)mentioning

confidence: 95%

“…Since VEGF cannot diffuse across biological membranes after binding to circulating sFlt-1, it cannot conduct signaling . sFlt-1 was significantly increased in the preeclamptic placenta at 11 weeks of gestation, with increased expression beginning 5 weeks before the onset of clinical symptoms .…”

Section: Placental Therapeutic Targetsmentioning

confidence: 99%

Placental Therapeutic Targets and Nanodelivery Systems

Liu

Gao

et al. 2022

Mol. Pharmaceutics

View full text Add to dashboard Cite

Pregnancy complications affect millions of women each year. Some of these diseases have high morbidity and mortality such as preeclampsia. At present, there is no safe and effective treatment for pregnancy complications, so it is still a difficult clinical problem. As many pregnancy complications are closely related to placental dysplasia, placenta-specific therapy, as an important method, is expected to be a safe, effective, and specific therapeutic strategy. This review explains in detail the placenta physiological structure, characteristics, and action mechanism of some biomolecules and signaling pathways that play roles in normal development and disorders of the development of the placenta, and how to use these biomolecules as therapeutic targets when the placenta disorder causes disease, combining the latest progress in the field of nanodelivery systems, so as to lay a foundation for the development of placenta-specific therapy of pregnancy complications.

show abstract

“…Serum VEGF was able to predict the need for peripartum hysterectomy by plotting RUC curves (AUC = 0.698, 95% CI 0.564–0.832, LR+2.4, LR−0.3, p = 0.004). This phenomenon provides a clear advantage for clinical application ( 16 – 18 ). However, due to the study's sample sizes and limited relevant reports, these remain controversial conclusions.…”

Section: Biomarkersmentioning

confidence: 99%

Potential Serum Biomarkers in Prenatal Diagnosis of Placenta Accreta Spectrum

Zhang

2022

Front. Med.

View full text Add to dashboard Cite

Placenta accreta spectrum (PAS) refers to the abnormal invasion of trophoblastic tissues. Because of its increasing morbidity and possibility of catastrophic outcomes, PAS requires an antenatal diagnosis and making full preparations in advance to realize safe delivery. Current clinical screening modalities for PAS are not always conclusive. Recently, it has been reported that bio-markers detected in maternal serum have the potential for predicting PAS during pregnancy. Some of these biomarkers, such as β-hcg, AFP, PAPP-A, and cffDNA, can be clinically detected. It is convenient for us to test and compare with standard threshold. However, how can we distinguishing PAS from other pregnancy complications through these biomarkers remains complicated. Some biomarkers are specific, such as microRNA and placenta-specific mRNA. They are stability and reliability. These biomarkers are currently research hotspots. This study aims to summarize the characteristics of the newly reported biomarkers and to point out their potential application and current limitations to provide a basis for future research. Finally, the combination of imageological examination and biomarkers will be an attractive future theme to study in diagnosing this challenging condition.

show abstract

Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa

Cited by 12 publications

References 35 publications

Expression of NF-κB and VEGF in normal placenta and placenta previa patients

Expression of NF-κB and VEGF in normal placenta and placenta previa patients

Placental Therapeutic Targets and Nanodelivery Systems

Potential Serum Biomarkers in Prenatal Diagnosis of Placenta Accreta Spectrum

Contact Info

Product

Resources

About